Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | -0.3x - -0.3x | -0.3x |
| Historical Pb Multiple | -4.5x - 1.8x | 1.1x |
| Fair Value | $0.0057 - $0.0063 | $0.0060 |
| Upside | -24.9% - -17.0% | -21.0% |
| Benchmarks | - | Full Ticker |
| Organigram Global Inc. | - | NasdaqGS:OGI |
| Cronos Group Inc. | - | NasdaqGM:CRON |
| Avicanna Inc. | - | OTCPK:AVCN.F |
| SNDL Inc. | - | NasdaqCM:SNDL |
| Aequus Pharmaceuticals Inc. | - | OTCPK:AQSZ.F |
| Humble Grow Co. | - | OTCPK:DLTN.F |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| OGI | CRON | AVCN.F | SNDL | AQSZ.F | DLTN.F | |||
| NasdaqGS:OGI | NasdaqGM:CRON | OTCPK:AVCN.F | NasdaqCM:SNDL | OTCPK:AQSZ.F | OTCPK:DLTN.F | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | -48.8% | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | NM | 158.8% | 44.4% | 43.6% | 18.2% | 24.7% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -104.2% | 61.8% | -1592.8% | -224.3% | -334.6% | -13.2% | ||
| Prior Fiscal Year | -153.8% | -80.1% | -364.0% | -18.5% | -232.7% | -43.0% | ||
| Latest Fiscal Year | -28.4% | 34.9% | -52.1% | -10.3% | -1163.1% | -24.6% | ||
| Latest Twelve Months | -31.7% | 34.9% | -27.3% | -10.3% | -647.6% | -27.7% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -23.2% | -2.6% | -546.4% | -48.5% | -587.8% | -127.3% | ||
| Prior Fiscal Year | -45.2% | -6.2% | -2571.2% | -13.4% | -358.9% | -174.2% | ||
| Latest Twelve Months | -18.1% | 3.8% | -496.1% | -8.1% | NM | -884.5% | ||
| Next Fiscal Year | -11.8% | -7.1% | 294.7% | 2.0% | #NUM! | 427.7% | ||
| Two Fiscal Years Forward | 0.4% | -7.1% | 148.6% | 6.2% | 51.3% | 84.7% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 1.2x | 5.9x | 1.4x | 0.6x | 1.6x | 0.1x | ||
| Price / LTM EPS | -3.7x | 16.8x | -4.9x | -5.5x | -0.2x | -0.2x | ||
| Price / Book | 0.6x | 0.6x | 19.6x | 0.5x | -0.1x | -0.4x | ||
| Price / Fwd Book | 0.7x | 0.7x | 57.5x | 0.5x | -0.2x | 0.2x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -0.1x | 0.6x | 19.6x | |||||
| Historical P/B Ratio | -4.5x | 1.1x | 1.8x | |||||
| Selected P/B Multiple | -0.3x | -0.3x | -0.3x | |||||
| (x) Book Value | (10) | (10) | (10) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | OGI | CRON | AVCN.F | SNDL | AQSZ.F | DLTN.F | |
| Value of Common Equity | 194 | 692 | 34 | 521 | 1 | 4 | |
| (/) Shares Outstanding | 133.8 | 382.5 | 110.2 | 257.3 | 171.3 | 365.3 | |
| Implied Stock Price | 1.45 | 1.81 | 0.31 | 2.03 | 0.01 | 0.01 | |
| FX Conversion Rate to Trading Currency | 1.44 | 1.00 | 1.44 | 1.44 | 1.44 | 1.44 | |
| Implied Stock Price (Trading Cur) | 1.01 | 1.81 | 0.21 | 1.41 | 0.00 | 0.01 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.44 | 1.00 | 1.44 | 1.44 | 1.44 | 1.44 | |